Literature DB >> 18044317

Olfactory groove meningiomas.

E Slavik1, D Radulović, G Tasić.   

Abstract

Meningiomas, usually histologically benign tumors, are originating from the arachnoidal cap cells normally present intracranially in varying sites. Olfactory groove meningeomas arise from the medline of the anterior fossa between the crista galli and the tuberculum sellae. The most common presenting symptoms are the visual field defects, epilepsy, and psychological change. They are often large before they are detected because of slowly asymptomatic growing in the interhemispheric space of the frontal lobes. This series is consisted of 29 patients suffering from olfactory groove meningiomas treated surgicaly between May 1992 and November 2003. The surgical results and complications are presented and analized, comparing them by the other reported series.

Entities:  

Mesh:

Year:  2007        PMID: 18044317     DOI: 10.2298/aci0702059s

Source DB:  PubMed          Journal:  Acta Chir Iugosl        ISSN: 0354-950X


  3 in total

Review 1.  Olfactory groove meningiomas: a retrospective study on 59 surgical cases.

Authors:  Alexandru Vlad Ciurea; Stefan Mircea Iencean; Radu Eugen Rizea; Felix Mircea Brehar
Journal:  Neurosurg Rev       Date:  2011-09-30       Impact factor: 3.042

2.  The endoscopic endonasal approach is not superior to the microscopic transcranial approach for anterior skull base meningiomas-a meta-analysis.

Authors:  Ivo S Muskens; Vanessa Briceno; Tom L Ouwehand; Joseph P Castlen; William B Gormley; Linda S Aglio; Amir H Zamanipoor Najafabadi; Wouter R van Furth; Timothy R Smith; Rania A Mekary; Marike L D Broekman
Journal:  Acta Neurochir (Wien)       Date:  2017-11-10       Impact factor: 2.216

3.  The endoscope-assisted supraorbital "keyhole" approach for anterior skull base meningiomas: an updated meta-analysis.

Authors:  Danyal Z Khan; Ivo S Muskens; Rania A Mekary; Amir H Zamanipoor Najafabadi; Adel E Helmy; Robert Reisch; Marike L D Broekman; Hani J Marcus
Journal:  Acta Neurochir (Wien)       Date:  2020-09-05       Impact factor: 2.216

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.